Mereo BioPharma's Setrusumab Demonstrates Dose-Dependent Bone Building and Trend in Fracture Reduction in Phase 2b ASTEROID Study in Adults with Osteogenesis Imperfecta
Stock Information for Mereo BioPharma Group plc
Loading
Please wait while we load your information from QuoteMedia.